Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1880MR)

This product GTTS-WQ1880MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1880MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11768MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ7031MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ493MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ7549MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ5731MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ5495MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ2341MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ3587MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW